Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company's principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica. Bespak's core business is the manufacture of inhaled drug delivery devices for life sciences partners and its operations are based in the United Kingdom. The Aesica business manufactures and sells active pharmaceutical ingredients (API), formulated pharmaceutical products and packaging services to the pharmaceutical industry and its operations are based in the United Kingdom and Europe. It offers its services to customers, such as pharmaceutical companies and life sciences. Its device products include metered dose inhalers, dry powder devices, actuators, dose counters, disposable auto-injectors, nasal devices and point-of-care diagnostics devices.
Industry, Sector and Symbol:
- 50 Day Moving Avg: $13.99
- 200 Day Moving Avg: $13.37
- 52 Week Range: $12.90 - $15.00
Sales & Book Value:
- Trailing P/E Ratio: 25.04
- P/E Growth: 0.00
- Annual Revenue: $385.41 million
- Price / Sales: N/A
- Book Value: $5.62 per share
- Price / Book: 2.67
Frequently Asked Questions for Consort Medical plc (NASDAQ:CSRMY)
What is Consort Medical plc's stock symbol?
Consort Medical plc trades on the NASDAQ under the ticker symbol "CSRMY."
Who are some of Consort Medical plc's key competitors?
Some companies that are related to Consort Medical plc include Tessera Holding Corporation (XPER), Himax Technologies (HIMX), OSI Systems (OSIS), Insight Enterprises (NSIT), CyberArk Software (CYBR), Atlas Air Worldwide Holdings (AAWW), Houghton Mifflin Harcourt Company (HMHC), Pacific Premier Bancorp (PPBI), Repligen Corporation (RGEN), Shenandoah Telecommunications Co (SHEN), Scholastic Corporation (SCHL), Westamerica Bancorporation (WABC), Gentherm (THRM), BMC Stock Holdings (BMCH), WisdomTree Investments (WETF), Sykes Enterprises, Incorporated (SYKE), NETGEAR (NTGR) and Boyd Group Income Trust Units (BFGIF).
Who are Consort Medical plc's key executives?
Consort Medical plc's management team includes the folowing people:
- Jonathan M. Glenn, Chief Executive, Executive Director
- Paul Hayes, Chief Financial Officer, Executive Director
- John W. Ilett, Group General Counsel, Company Secretary
- Keyvan Djamarani, Managing Director, Bespak
- Ian Muir, Managing Director, Aesica
- Peter J. Fellner, Non-Executive Independent Chairman of the Board
- Steve Crummett, Non-Executive Director
- Maria Charlotta Ginman-Jones, Non-Executive Director
- Andrew Joseph Hosty, Non-Executive Director
- Ian J. Nicholson, Non-Executive Director
How do I buy Consort Medical plc stock?
Shares of Consort Medical plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Consort Medical plc's stock price today?
MarketBeat Community Rating for Consort Medical plc (NASDAQ CSRMY)MarketBeat's community ratings are surveys of what our community members think about Consort Medical plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Consort Medical plc stock can currently be purchased for approximately $15.00.
Consensus Ratings for Consort Medical plc (NASDAQ:CSRMY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Consort Medical plc (NASDAQ:CSRMY)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Consort Medical plc (NASDAQ:CSRMY)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Consort Medical plc (NASDAQ:CSRMY)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Consort Medical plc (NASDAQ:CSRMY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Consort Medical plc (NASDAQ:CSRMY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Consort Medical plc (NASDAQ:CSRMY)
Latest Headlines for Consort Medical plc (NASDAQ:CSRMY)
Consort Medical plc (CSRMY) Chart for Wednesday, July, 26, 2017